Exhibit 99.1 Shimmick Corporation Announces Third Quarter 2025 Results Irvine, CA, November 13, 2025 – Shimmick Corp. (NASDAQ: SHIM), a leading infrastructure solutions provider in water, electrical and other critical infrastructure construction services, today announced financial results for the third quarter ended October 3, 2025. Third Quarter 2025 and Recent Highlights "Our transformation is clearly gaining momentum, supported by strong execution and solid operating performance," said Ural Yal, Chief Ex ...

Business Operations - As of September 30, 2025, the company operates approximately 3,950 billboards with about 7,570 advertising faces, having increased its billboard count from approximately 2,900 since 2015[188] - The broadband services segment has approximately 48,900 customers, including 18,700 fiber subscribers, and 44,500 fiber passings completed as of September 30, 2025[190] - The company has expanded its surety insurance business to all 50 states and the District of Columbia, enhancing its market reach significantly[189] - The company plans to continue expanding its broadband services in Arizona, Florida, Nevada, Utah, and other locations, focusing on fiber-to-the-home infrastructure[190] - The company aims to grow its outdoor billboard advertising business through acquisitions of existing billboard assets at attractive prices[188] Financial Performance - In the third quarter of fiscal 2025, total revenues increased by 3.7% to $28,734,355 compared to $27,700,936 in the third quarter of fiscal 2024[203] - Billboard rentals generated $11,788,400, accounting for 41.1% of total revenues, while broadband services contributed $10,150,921, representing 35.3% of total revenues[203] - Premiums earned from the insurance subsidiary increased by 3.9% to $5,636,732, maintaining a consistent 19.6% of total revenues[203] - The company reported a net loss attributable to common stockholders of $5,577,273 in the first nine months of fiscal 2025, translating to a loss per share of $0.18, compared to a net loss of $6,638,436 or $0.21 per share in the same period of fiscal 2024[220] - Total revenues for the first nine months of fiscal 2025 were $84,668,519, representing a 5.4% increase from $80,341,450 in the first nine months of fiscal 2024[213] Costs and Expenses - Employee costs were $8,434,406, or 29.3% of total revenues, slightly down from 30.0% in the previous year[205][206] - Total costs and expenses decreased to $87,338,564 in the first nine months of fiscal 2025 from $87,536,368 in the same period of fiscal 2024, with the percentage of total revenues dropping from 109.0% to 103.2%[214] - Professional fees increased to $1,318,570, or 4.6% of total revenues, in Q3 fiscal 2025, up from $1,052,542, or 3.8% of total revenues, in Q3 fiscal 2024[212] - Employee costs decreased to $25,898,396, or 30.6% of total revenues, in the first nine months of fiscal 2025, down from $28,764,730, or 35.8% of total revenues, in the same period of fiscal 2024[214] Investments and Acquisitions - The acquisition of 24th Street Asset Management LLC was completed for a total consideration of $5,016,494, which included $2,759,072 in cash at closing and additional cash subject to holdback[192] - The company has invested approximately $19 million in CB&T Holding Corporation, representing 15.6% of its outstanding common stock[194] - The company invested approximately $3 million in MyBundle.TV Inc. in July 2023, focusing on the broadband industry[198] - The company plans to continue acquiring billboard locations, insurance businesses, and broadband service providers to generate positive cash flows[246] Cash Flow and Financing - Net cash provided by operating activities was $12,050,193 for the first nine months of fiscal 2025, slightly down from $12,117,191 in the same period of fiscal 2024[242] - Net cash used in investing activities was $2,277,900 for the first nine months of fiscal 2025, a significant decrease from $29,893,384 in the same period of fiscal 2024[243] - Net cash provided by financing activities was $5,259,282 during the first nine months of fiscal 2025, compared to net cash used of $48,879,743 in the same period of fiscal 2024[244] - The company has raised funds through various means, including public offerings and term loan financing, to support its operations and growth initiatives[249] Debt and Financial Covenants - As of September 30, 2025, Link's long-term debt includes approximately $25,900,000 in Term Loan borrowings, with $880,000 classified as current[256] - Link is required to maintain a consolidated leverage ratio of not greater than 3.50 to 1.00 starting from the fiscal quarter ended June 30, 2024, reducing to 3.00 to 1.00 by December 31, 2027[257] - Future acquisitions may require additional capital through long-term debt borrowings or the sale of securities if current cash and securities are insufficient[269] - The company is subject to financial covenants that limit its ability to incur additional indebtedness and make acquisitions[269] Market and Operational Risks - The company may need to take steps to avoid being deemed an investment company under the Investment Company Act, which could impact its operations and financial condition[271] - The company's operations are conducted entirely within the U.S., resulting in no significant exposure to foreign currency exchange rate risk[277] - The preparation of financial statements requires estimates affecting reported amounts of assets, liabilities, revenue, and expenses, based on historical results and reasonable assumptions[279] - There have been no material changes to the critical accounting policies and estimates as previously disclosed in the 2024 Form 10-K[279] Shareholder Actions - The company repurchased 111,323 shares of its Class A common stock for a total cost of approximately $1.6 million under the Share Repurchase Program[247]

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Commission File Number 001-38114 AVENUE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 47-4113275 (State or ...

Revenue and Sales Performance - The installed base of OGM systems grew to 384 as of September 30, 2025, representing a 4% increase from 368 as of September 30, 2024[136] - A total of 8,390 flowcells were sold in the three-month period ended September 30, 2025, a 7% increase from 7,835 flowcells sold in the same period of 2024[136] - Product revenue for the three months ended September 30, 2025, was $6,934,000, compared to $6,021,000 for the same period in 2024, reflecting a year-over-year increase[142] - Total revenue for the three months ended September 30, 2025, was $7.37 million, a 21% increase from $6.07 million in 2024[150] - Product revenue increased by $0.9 million, or 15%, to $6.9 million for the three months ended September 30, 2025, compared to $6.0 million for the same period in 2024[151] - Service and other revenue increased by $0.4 million, or 733%, to $0.4 million for the three months ended September 30, 2025, compared to the same period in 2024[152] - Product revenue decreased by $0.1 million, or 1%, to $19.2 million for the nine months ended September 30, 2025, compared to $19.4 million for the same period in 2024, driven by a 30% decrease in instrument sales[165] - Service and other revenue decreased by $1.9 million, or 60%, for the nine months ended September 30, 2025, due to the discontinuation of certain clinical service offerings, contributing no revenue in 2025 compared to $1.7 million in 2024[166] Financial Performance and Losses - The net loss for the three months ended September 30, 2025, was $8.5 million, with an accumulated deficit of $711.7 million as of the same date[147] - The company incurred net losses of $18.5 million for the nine months ended September 30, 2025, compared to $91.9 million in 2024, with cash and cash equivalents of $3.1 million as of September 30, 2025[178] - Net loss for the three months ended September 30, 2025, was $8.5 million, an improvement of $35.7 million, or 81%, from a net loss of $44.2 million in 2024[150] Operating Expenses and Cost Management - Total operating expenses decreased by $23.5 million, or 66%, to $11.9 million for the three months ended September 30, 2025, compared to $35.5 million in 2024[150] - Cost of product revenue decreased by $10.4 million, or 73%, to $3.8 million for the three months ended September 30, 2025, compared to $14.3 million in 2024[153] - Research and development expenses decreased by $1.9 million, or 40%, to $2.8 million for the three months ended September 30, 2025, compared to $4.7 million in 2024[157] - Selling, general and administrative expenses decreased by $0.4 million, or 4%, to $9.1 million for the three months ended September 30, 2025, compared to $9.5 million in 2024[158] - Research and Development (R&D) expenses decreased by $13.2 million, or 62%, to $8.1 million for the nine months ended September 30, 2025, due to headcount reductions and decreased consulting fees[172] - Selling, General and Administrative (SG&A) expenses decreased by $13.7 million, or 34%, to $26.4 million for the nine months ended September 30, 2025, driven by reductions in salaries and professional fees[173] Cash Flow and Liquidity - As of September 30, 2025, the company had $3.1 million in cash and cash equivalents, $18.5 million in short-term investments, and $10.3 million in restricted short-term investments[194] - Net cash used in operating activities was $12.2 million for the nine months ended September 30, 2025, a decrease of $50.2 million compared to $62.4 million in the same period in 2024[198] - Net cash provided by financing activities was $22.4 million during the nine months ended September 30, 2025, compared to net cash used of $17.6 million in the same period in 2024, an increase of $40.0 million[200] - The company expects to require additional capital to fund operating expenses and capital expenditures into the third quarter of 2026[192] - The company anticipates that its available cash balance will not be sufficient to operate its business for the next twelve months, indicating substantial doubt about its ability to continue as a going concern[194] Market and Operational Challenges - The company has experienced a slowdown in its Asia Pacific business, negatively impacting its manufacturing partners reliant on government funding[137] - The company is closely monitoring the potential impact of the U.S. government shutdown on its manufacturing partners and customers[141] - The company expects to continue incurring significant expenses and operating losses, raising substantial doubt about its ability to continue as a going concern within the next 12 months[147] Stock and Securities - The combined purchase price for each share of common stock and accompanying January Purchase Warrant was $15.120, with gross proceeds from the January 2025 offering approximately $10.0 million[187] - The September 2025 Offering included 4.9 million shares of common stock and generated approximately $10.0 million in gross proceeds[189] - The company sold approximately 2.0 million shares of common stock under the ATM Agreement at an average price of $3.68 per share, generating gross proceeds of approximately $7.4 million[203] - The company has a universal shelf registration statement allowing for aggregate offerings of up to $400.0 million of various securities[202] Accounting and Reporting - The management's discussion and analysis is based on unaudited condensed consolidated financial statements prepared in accordance with generally accepted accounting principles[206] - There have been no changes to critical accounting policies and estimates during the nine months ended September 30, 2025[207] - The company is not required to provide quantitative and qualitative disclosures about market risk as a smaller reporting company[210]

Financial Performance - Total revenue for Q3 2025 was $43.7 million, a decline of 9.4% year-over-year and 0.7% sequentially [6]. - Net loss for the quarter was $3.0 million, compared to a net loss of $1.3 million in the same period last year [7]. - Adjusted EBITDA loss was $1.2 million, compared to breakeven in the same period last year [7]. - Revenue for Q3 2025 was $43.734 million, a decrease of 9.5% compared to $48.280 million in Q3 2024 [27]. - Gross profit for Q3 2025 was $23.322 million, down from $25.602 million in Q3 2024, reflecting a gross margin of 53.3% [27]. - Operating loss for Q3 2025 was $2.731 million, an improvement from a loss of $6.746 million in Q3 2024 [27]. - Net loss attributable to common stockholders for Q3 2025 was $3.335 million, compared to a loss of $1.510 million in Q3 2024 [27]. - Adjusted EBITDA for the nine months ended September 30, 2025, was a loss of $3.711 million, compared to a gain of $2.919 million in the same period of 2024 [31]. Customer Metrics - DTC total orders were 619,000, a decline of 12.5% year-over-year, primarily due to lower advertising spend [12]. - DTC active customers totaled 660,000, a decrease of 7.0% year-over-year, driven by reduced advertising spend [13]. Cost Management - Operating expenses decreased by 19.5% to $26.1 million compared to $32.3 million in the prior year [8]. - The company executed a reduction in force in November, expected to result in approximately $5 million of annualized savings [7]. Future Guidance - Full-year 2025 revenue is expected to be between $172.5 million and $175 million, tracking to the lower end of the guidance range [19]. - Fourth-quarter revenue is expected to remain roughly flat sequentially, with full-year Adjusted EBITDA still expected to be within prior guidance [19]. Balance Sheet - Total current assets decreased to $34.515 million as of September 30, 2025, from $44.941 million as of December 31, 2024 [25]. - Total liabilities decreased to $46.023 million as of September 30, 2025, from $48.787 million as of December 31, 2024 [25]. - Cash, cash equivalents, and restricted cash at the end of Q3 2025 were $12.309 million, down from $55.589 million at the end of Q3 2024 [29]. - Inventory as of September 30, 2025, was $19.984 million, slightly up from $19.351 million as of December 31, 2024 [25]. - The company incurred $2.848 million in cash paid for acquisitions during the nine months ended September 30, 2025 [29].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39990 Registrant's telephone number, includ ...

Financial Performance - As of September 30, 2025, Elicio Therapeutics reported total assets of $28,284,000, an increase from $28,178,000 as of December 31, 2024[19] - The company’s cash and cash equivalents increased to $20,611,000 from $17,618,000, reflecting a growth of approximately 16.9%[19] - Total operating expenses for the three months ended September 30, 2025, were $8,045,000, a decrease of 22.1% compared to $10,344,000 for the same period in 2024[21] - The net loss for the three months ended September 30, 2025, was $10,083,000, compared to a net loss of $18,838,000 for the same period in 2024, representing a reduction of 46.6%[21] - For the nine months ended September 30, 2025, the company reported a net loss of $31.85 million, an improvement from a net loss of $37.89 million for the same period in 2024, representing a decrease of approximately 15.4%[29] - The net loss for the nine months ended September 30, 2025 was $31.9 million, a 16% improvement from a net loss of $37.9 million in the same period of 2024[142] Expenses and Liabilities - Total operating expenses for the three months ended September 30, 2025, were $8,045,000, a decrease of 22.1% compared to $10,344,000 for the same period in 2024[21] - Research and development expenses decreased to $5,039,000 for the three months ended September 30, 2025, down 30.1% from $7,208,000 in the prior year[21] - The company’s total liabilities decreased significantly to $24,468,000 from $39,490,000, indicating a reduction of approximately 38.1%[19] - Total accrued expenses decreased from $8.415 million on December 31, 2024, to $5.213 million on September 30, 2025[53] - Research and development expenses for the nine months ended September 30, 2025, totaled $20.7 million, compared to $24.0 million for the same period in 2024, indicating a decrease of 13.8%[114] Cash Flow and Financing - The company had cash and cash equivalents of $20.61 million as of September 30, 2025, compared to $26.02 million at the end of 2024, indicating a decrease of about 20.8%[33] - Net cash used in operating activities for the nine months ended September 30, 2025, was $30.16 million, slightly higher than $28.32 million for the same period in 2024[29] - The company generated net cash provided by financing activities of $31.83 million for the nine months ended September 30, 2025, compared to $42.09 million for the same period in 2024, a decrease of approximately 24.4%[29] - The company plans to address its liquidity concerns through potential public offerings, private placements, and strategic partnerships, although there is no assurance these plans will be successful[33] - The company expects to incur substantial expenditures for the development of its product candidates, necessitating additional financing in the foreseeable future[33] Stock and Equity - The weighted average common shares outstanding for the three months ended September 30, 2025, were 16,692,476, an increase from 13,582,345 in the prior year[21] - Elicio Therapeutics issued 1,261,830 shares of common stock from the January 2025 Offering, net of issuance costs of $0.8 million[24] - The Company raised approximately $11.4 million in net proceeds from the 2024 ATM Program by selling 1,176,449 shares at a weighted average price of $9.68 per share[60] - The January 2025 Offering resulted in net proceeds of $9.2 million after deducting fees, selling 1,261,830 shares at a combined offering price of $7.925[64] - As of September 30, 2025, there were 806,700 shares of common stock available for issuance under the Company's equity incentive plans[66] Legal and Compliance - The company does not believe it is currently involved in any legal proceedings that would have a material adverse effect on its business[169] - There have been no material changes in the company's risk factors from those described in the Form 10-K[171] - The company has not engaged in any unregistered sales of equity securities during the reporting period[172] - The company has not defaulted on any senior securities[173] Future Outlook - Cash on hand is projected to fund operations through the second quarter of 2026, but there is substantial doubt about the company's ability to continue as a going concern[122] - The company expects its cash and cash equivalents to be sufficient to fund operations through the second quarter of 2026, but may require additional financing[154] - The company plans to address its funding needs through the sale of common stock or other securities, debt financings, or strategic partnerships[156] - The company achieved a milestone related to ongoing clinical trials, recording a license expense of $0.4 million during the nine months ended September 30, 2024[86] Internal Controls and Governance - As of September 30, 2025, the company's disclosure controls and procedures were evaluated as effective by the management team[166] - There were no changes in the internal control over financial reporting during the quarter ended September 30, 2025, that materially affected the internal control[167] - The company continues to take advantage of exemptions from certain disclosure requirements as a smaller reporting company[162]

Financial Performance - Revenue for Q3 2025 was $20.7 million, a 9% increase compared to Q3 2024[3] - Gross profit was $14.0 million, representing 67.5% of revenue, compared to 67.8% in Q3 2024[4] - Operating expenses decreased to $21.5 million from $22.2 million in Q3 2024, primarily due to lower compensation and benefits[6] - Loss from operations improved to $7.6 million in Q3 2025, compared to a loss of $9.4 million in Q3 2024[7] - Net loss for Q3 2025 was $8.6 million, down from $10.4 million in Q3 2024[8] Cash and Financing - Cash and cash equivalents totaled $29.7 million as of September 30, 2025[8] - The company secured a credit facility of up to $70.0 million from Perceptive Advisors, with an initial loan of $60.0 million[10] Growth and Strategy - Full year 2025 revenue guidance revised to project at least 16% growth over 2024[9] - The company achieved its 2025 hiring target in the U.S. sales organization[5] - The addition of new customers and growing international sales contributed to revenue growth[3]

Cibus Reports Third Quarter Financial Results and Provides Year-to- Date Business Update for 2025 With the addition of Centro Internacional de Agricultura Tropical (CIAT) in the quarter, Cibus now has 5 LATAM Rice customers as momentum continues toward achieving 2027 targeted initial LATAM Rice revenue On track to deliver HT traits to Latin American customer in Q4 2025 with field trials expected to commence by year end Engaged strategic growth advisory firm AgVayā to introduce Indian Rice growers to new sol ...

Financial Performance - Net loss for Q3 2025 was $24.3 million, significantly reduced from $201.5 million in the same quarter last year[16]. - Total revenue for Q3 2025 was $615,000, a decrease of 63.2% compared to $1,667,000 in Q3 2024[33]. - Net loss for Q3 2025 was $24,303,000, compared to a net loss of $201,459,000 in Q3 2024, reflecting a significant reduction in losses[33]. - Basic and diluted net loss per share of Class A common stock was $(0.44) for Q3 2025, compared to $(7.63) for Q3 2024[33]. Cash and Liquidity - Cash and cash equivalents as of September 30, 2025, were $23.9 million, expected to fund operations into early Q2 2026[16]. - Cash and cash equivalents increased to $23,886,000 as of September 30, 2025, from $14,433,000 at the end of 2024, marking a 65.7% increase[30]. - The company generated $50,100,000 in proceeds from issuances of securities during the nine months ended September 30, 2025[34]. Expenses - R&D expenses decreased to $10.8 million for Q3 2025, down from $13.0 million in the prior year, primarily due to cost reduction initiatives[16]. - SG&A expenses were $5.3 million for Q3 2025, compared to $7.7 million in the year-ago period, reflecting cost-saving measures[16]. - Research and development expenses for the nine months ended September 30, 2025, were $34,811,000, down from $37,996,000 in the same period of 2024[33]. Assets and Liabilities - Total assets decreased to $330,226,000 as of September 30, 2025, from $350,069,000 at the end of 2024, a decline of 5.7%[30]. - Total liabilities increased to $278,197,000 as of September 30, 2025, compared to $252,238,000 at the end of 2024, an increase of 10.3%[32]. - Cibus' royalty liability to related parties increased to $225,517,000 as of September 30, 2025, from $199,442,000 at the end of 2024, an increase of 13.1%[30]. - The company reported a goodwill impairment of $20,950,000 for the nine months ended September 30, 2025, compared to $181,432,000 in the same period of 2024[33]. Business Development - Cibus signed seven Rice customer agreements, representing approximately 5-7 million addressable acres and a potential annual royalty opportunity exceeding $200 million[2]. - Cibus expects to deliver HT traits to Latin American customers in Q4 2025, with field trials commencing by year-end[1]. - Positive field trial results for HT2 in Canola were reported, with traits available for seed licensing partners[1]. - The company completed pre-commercial pilot runs for biofragrance products, targeting commercial expansion in 2026[1]. - Cibus appointed Kimberly A. Box and Craig Wichner to its Board of Directors to enhance commercial expansion support[1]. Future Outlook - Cibus aims to achieve a reduced annual net cash usage of $30 million by 2026[1].